Rating Change
HC Wainwright & Co. reiterated its Buy rating on Palisade Bio, Inc. (NASDAQ:PALI) on October 13, 2026.
reiterateNASDAQ:PALI
HC Wainwright & Co. Reiterates Buy Rating on Palisade Bio, Inc. (PALI)
HC Wainwright & Co. reiterated its Buy rating on Palisade Bio, Inc.
At publication ·
What changed
Palisade Bio, Inc. (NASDAQ:PALI) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $1.50
- Market capitalization
- $327.1M
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Palisade Bio (PALI) on October 13, 2026, with the stock trading at $1.50 and a market cap of $327.1 million.
Market Context
Palisade Bio, Inc. operates in the Healthcare sector. The stock currently trades at $1.50 with a market capitalization of $327.1M. The stock has declined 23.0% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Palisade Bio, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Palisade Bio, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 13, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 09, 2026 | Raymond James | Outperform | N/A |
| Sep 23, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 23, 2026 | Oppenheimer | Outperform | N/A |
| Apr 09, 2026 | Wolfe Research | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View PALI Stock Page
Frequently Asked Questions
What does the Buy rating mean for PALI?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Palisade Bio, Inc. (NASDAQ:PALI). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PALI forecast page.